- Open Access
In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate
Virology Journal volume 6, Article number: 55 (2009)
Poxvirus-vectored vaccines against infectious diseases and cancer are currently under development. We hypothesized that the extensive use of poxvirus-vectored vaccine in future might result in co-infection and recombination between the vaccine virus and naturally occurring poxviruses, resulting in hybrid viruses with unpredictable characteristics. Previously, we confirmed that co-infecting in vitro a Modified vaccinia virus Ankara (MVA) strain engineered to express influenza virus haemagglutinin (HA) and nucleoprotein (NP) genes with a naturally occurring cowpox virus (CPXV-NOH1) resulted in recombinant progeny viruses (H Hansen, MI Okeke, Ø Nilssen, T Traavik, Vaccine 23: 499–506, 2004). In this study we analyzed the biological properties of parental and progeny hybrid viruses.
Five CPXV/MVA progeny viruses were isolated based on plaque phenotype and the expression of influenza virus HA protein. Progeny hybrid viruses displayed in vitro cell line tropism of CPXV-NOH1, but not that of MVA. The HA transgene or its expression was lost on serial passage of transgenic viruses and the speed at which HA expression was lost varied with cell lines. The HA transgene in the progeny viruses or its expression was stable in African Green Monkey derived Vero cells but became unstable in rat derived IEC-6 cells. Hybrid viruses lacking the HA transgene have higher levels of virus multiplication in mammalian cell lines and produced more enveloped virions than the transgene positive progenitor virus strain. Analysis of the subcellular localization of the transgenic HA protein showed that neither virus strain nor cell line have effect on the subcellular targets of the HA protein. The influenza virus HA protein was targeted to enveloped virions, plasma membrane, Golgi apparatus and cytoplasmic vesicles.
Our results suggest that homologous recombination between poxvirus-vectored vaccine and naturally circulating poxviruses, genetic instability of the transgene, accumulation of non-transgene expressing vectors or hybrid virus progenies, as well as cell line/type specific selection against the transgene are potential complications that may result if poxvirus vectored vaccines are extensively used in animals and man.
The family Poxviridae consists of large double stranded DNA viruses that replicate in the cytoplasm of infected cells [1, 2]. Within this family, vaccinia and cowpox viruses are members of the genus Orthopoxvirus. Poxviruses are increasingly being used as vectors for efficient gene expression in vitro and in vivo [2–4]. The future use of poxvirus vectors for delivery of prophylactic and therapeutic vaccines has raised potential biosafety concerns. Putative risks associated with the use of genetically modified poxviruses as vaccines include virulence of the vector, stability of inserted transgene, potential transmission to non-target species and recombination between the vaccine vector and a naturally circulating poxvirus [5, 6]. The risks of virulence and spread to non-target species have been addressed in part by the use of attenuated strains like modified vaccinia virus Ankara (MVA). MVA multiplication seems to be restricted in most mammalian cells. So far it has only been shown to carry out full productive infections in BHK-21 and IEC-6 cells respectively [7, 8]. MVA is considered apathogenic even when administered in high doses to immune deficient animals [9–11]. Several MVA vectored vaccines against infectious diseases and cancers are in various phases of field and clinical trials [12–16].
MVA can be genetically modified by recombination with a naturally occurring wild type orthopoxvirus (OPV) during mixed infection. Alternatively, the transgene in the MVA vector can be recombined into a replication competent poxvirus during co-infection. To assess the risk of recombination, it is essential that the MVA vector and a naturally circulating poxvirus co-infect the same cell or host. The potential widespread use of MVA vectored vaccines (especially in wild-life and free ranging domestic animals), and therapeutic vaccination with MVA against emerging OPV epidemics are likely scenarios for mixed infection between vaccine strains of OPVs and naturally circulating relatives. Post exposure application of MVA to treat pre-existing OPV infection is a likely scenario for co-infection. Indeed post exposure application of MVA has been shown to protect against lethal OPV infection . Poxviruses undergo a high frequency of homologous recombination in the cytoplasm of infected cells [18–22]. Poxvirus recombination, which is inextricably linked with DNA replication requires 12 bp end sequence homology between the recombinogenetic templates [23, 24]. Thus, even the highly attenuated MVA can undergo homologous recombination in non-permissive cells or hosts since DNA replication is unimpaired. Although homologous recombination is the method of choice for generating transgenic MVA vectored vaccines , studies on recombination between transgenic MVA vectors and wild type poxviruses are miniscule. Analysis of co-infection and recombination between MVA vectored vaccines and wild type OPVs is a safer model for evaluating the potential consequences of recombination between poxvirus vectored vaccines and naturally circulating OPVs than using multiplication competent poxvirus vectors. In addition, the characterization of hybrid progenies arising from recombination between transgenic MVA and wild type OPVs will provide valuable information on poxvirus host range, morphogenesis, cytopathogenicity (CPE), replication fitness, transgene stability and transgenic protein localization.
Previously, we have isolated and genetically mapped recombinant viruses obtained from co-infection of cells with a transgenic MVA strain (MVA-HANP) engineered to express the influenza virus haemagglutinin (HA) and nucleoprotein (NP) genes and a naturally circulating cowpox virus (CPXV-NOH1) . In the present study we analyzed the biological properties of parental and progeny hybrid viruses. We show that the transgene or its expression was lost following serial passage of some of the hybrid viruses in mammalian cells, and that the resulting transgene negative virus strains have an enhanced virus multiplication in several mammalian cell lines. In addition, the stability of the transgene or the loss of its expression varies with cell lines used for virus multiplication.
Cell line permissivity, cytopathogenicity and plaque phenotypes
To investigate the in vitro host range, cytopathogenicity and plaque phenotypes of parental and progeny viruses, thirteen mammalian cell lines from various species and tissues were infected with viruses under study. The parental CPXV-NOH1 has a broad host range and multiplied in all the cell lines (Figure 1A). Caco-2, RK-13, IEC-6 and Vero cells supported high virus multiplication while virus production was lower in A549, CHO-K1 and Hutu-80 cells (Figure 1A). MVA-HANP multiplied only in IEC-6 and BHK-21 cells (Figure 1B). Detailed analysis of MVA multiplication and morphogenesis was described in a previous report . The in vitro host range of Rec 1 is similar to CPXV-NOH1 except that higher levels of virus multiplication were obtained in many cell lines (Figure 1C). Rec 2 underwent productive infection in all the cell lines. However, unlike CPXV-NOH1 and Rec 1, its multiplication was characterized by high production of extracellular virions (Figure 1D). In fact, in A549 cells more virions were released to the medium than intracellular virus particles (Figure 1D). Compared to CPXV-NOHI, Rec 1 and Rec 2, Rec 3 had reduced virus multiplication in all the cell lines (Figure 1E). The transgene negative derivatives of Rec 3 (Rec 3a and Rec 3b) had in vitro host ranges comparable to Rec 3, except that virus production was more efficient (Figures 1F, G). Unlike CPXV-NOH1, Rec 1 and Rec 2, no extracellular virions were detected in FHs74int cells infected with Rec 3 and its transgene negative derivatives 3a and 3b (Figure 1).
CPXV-NOHI produced low, moderate and high CPE in one, seven and five cell lines respectively (Table 1). MVA-HANP gave low or no CPE in all the cell lines except BHK-21 and IEC-6 cells where it produced high and moderate CPE, respectively. Rec 1 had moderate to very high CPE in all the cell lines tested except Caco-2. Compared to parental CPXV-NOH1, Rec 1 showed enhanced CPE in seven cell lines (Table 1). Similarly, Rec 2 resulted in higher CPE in most cell lines compared to parental CPXV-NOHI. Conversely, Rec 3 resulted in lower CPE compared to CPXV-NOHI in most cell lines except RK-13 and CHO-KI cells. Interestingly, transgene negative derivatives of Rec 3 (Rec 3a and Rec 3b) produced higher CPE in many cell lines compared to the transgene positive Rec 3 (Table 1). In particular, Rec 3b is the most cytopathogenic of virus strains investigated in this study. The plaque phenotypes of parental and progeny viruses were examined in thirteen mammalian cell lines. Previously, we have reported the plaque phenotypes of these viruses in Vero cells . However, MVA does not form distinct plaques in Vero cells and thus comparison of plaque phenotypes of hybrid viruses was made only with the parental CPXV-NOH1 . Therefore, we re-examined plaque phenotypes of parental and hybrid viruses in rat IEC-6, a cell line in which MVA forms very clear plaques . CPXV-NOH1 produced large lytic plaques in IEC-6 cells (Figure 2A) and the other twelve cell lines (data not shown). In permissive IEC-6 cells, MVA-HANP plaques were small, non-lytic with characteristic comet (satellite) formation (Figure 2B). The plaque phenotype of Rec 1 in IEC-6 cells (Figure 2C) and other cell lines (data not shown) was similar to CPXV-NOHI except that plaques were larger in size. Rec 2 produced small plaques and comets in IEC-6 cells (Figure 2D). Comet formation was enhanced in Rec 2 compared to MVA-HANP although the size of the primary plaque is larger in the latter. Rec 3 produced large semi-lytic plaques with some undetached cells in the center of the plaque (Figure 2E). Rec 3a plaques were very large and lytic (Figure 2F). Rec 3b produced the largest plaque size in IEC-6 cells (Fig. 2G) and other cell lines and its plaques were characterized by high level of cell detachment and syncytia formation. Taken in tandem, the progeny viruses displayed parental and non-parental characteristics with respect to in vitro host range, CPE and plaque phenotypes.
Virus multiplication at low and high multiplicity of infection (m.o.i)
Multistep multiplication at low m.o.i and single step multiplication at high m.o.i are standard methods for quantifying infectious virus production . The low m.o.i analysis was carried out at a m.o.i of 0.01 pfu per cell. The low m.o.i kinetics of virions produced in the cell and liberated into the medium is summarized in Figures 3A and 3B. At low m.o.i, CPXV-NOHI virion production in the cell increased exponentially after a short lag period, reaching 8.35 logs at 60 hpi (Figure 3A). Release of virions into the medium was inefficient and was characterized by 24 hours lag period and low virus yield (Figure 3B). MVA-HANP multiplied poorly in Vero cells (Figures 3A, B). Intracellular virus production in Rec 1 was very high as evidenced by very high titre (9.12 logs) and yield (5.4 logs). Although the release of Rec 1 virions from Vero cells infected at low moi was delayed (36 hpi) compared to other strains that already released virons (20 hpi or less), it was a short and spontaneous single burst (Figure 3B). This suggested that Rec 1 is a very lytic virus. Rec 2 form small plaques but virion production appears unhindered. Intracellular virus multiplication was gradually reaching a titer of 8 logs at late times post infection (Figure 3A). Expectedly, 35% of Rec 2 total infectivity was liberated into the medium (Figure 3B). This is not surprising since Rec 2 is very efficient in producing comets. Multiplication kinetics of Rec 3 showed that virion production or its spread was less efficient than other strains infected at lower m.o.i. Intracellular and extracellular virions produced by Rec 3 were approximately 1 log or more lower than that of other strains (Figures 3A, B). Interestingly, the HA negative viruses (Rec 3a and Rec 3b) derived from Rec 3 by the spontaneous deletion of the HA following serial passage in Vero cells  showed improved levels of virus multiplication than their ancestor. Indeed at various time points post infection, Rec 3a and Rec 3b virus titre (in the cell and medium) were at least one log higher than Rec 3 (Figures 3A, B). At this juncture, we do not know the reason for the increase in virus production in the HA negative Rec 3a and Rec 3b.
Virus production and spread is influenced by the m.o.i. Thus low m.o.i multi step conditions may generate different multiplication profile from synchronized single step conditions at high m.o.i . Thus we generated multiplication profiles of test virus strains following synchronized infection at a m.o.i of 5 pfu per cell. The results are summarized in Figures 3C and 3D. CPXV-NOHI has similar multiplication kinetics with all progeny viruses from adsorption to 24 hpi, although Rec 3 has the lowest intracellular and extracellular virus titres (Figures 3C, D). MVA-HANP performs limited virus multiplication in Vero cells. Consistent with what was obtained under multi-step conditions, transgene negative progenies of Rec 3 (Rec 3a and Rec 3b) have higher levels of virus multiplication compared to Rec 3 (Figures 3C, D). Thus, compared to the HA positive progenitor strain (Rec 3), the HA negative derivatives (Rec 3a and Rec 3b) have enhanced virus multiplication at both low and high m.o.i.
Stability of the transgene in mammalian cells
Since virus tropism is dependent on the host or cell type, we hypothesized that the stability of the influenza virus HA insert in the transgenic viruses may vary in different cell types or lines. To our knowledge, the stability of the transgene in MVA vectored vaccines in different cell types or hosts has not been reported. To address this hypothesis, transgene positive viruses were passaged in Vero and IEC-6 cells for five times at a m.o.i of 0.01 pfu per cell. Consistent with our previous report, the HA phenotype of Rec 3 was unstable in Vero cells . By the 4th passage, HA + plaques were undetected in Vero cells (Figure 4A). The HA phenotype of Rec 1 in Vero cells was stable up to passage 3. However, by passage 5, only 58% of Rec 1 plaques were HA + (Figure 4A). The HA + phenotype of Rec 2 was very stable in Vero cells across several passages (Figure 4A). These results suggested varying degrees of stability of the transgene in the progeny transgenic viruses. The stability of the HA + phenotype of MVA-HANP in Vero cells was not included because of low virus titres. The HA + phenotype of all transgenic viruses including MVA-HANP was unstable in IEC-6 cells (Figure 4B). The highest level of instability was observed with MVA-HANP and Rec 3. In both viruses, the HA + plaques were undetectable at passage 3 (Figure 4B). Beyond passage 3, the HA + phenotype of Rec 1 and Rec 2 were unstable to the extent that approximately 20% of the plaques were HA + at passage 5 (Figure 4B). Also, the reduction in the number of HA expressing viruses (MVA-HANP, Rec 3) was accompanied by a dramatic increase in the number of none HA expressing viruses (data not shown). There was no significant variation in the titre of each transgenic virus in Vero or IEC-6 cells at each serial passage (data not shown). Thus, these results suggest that the cell line or cell type used for virus multiplication might influence the stability of the transgene inserted into poxvirus vectors or determine the speed at which the expression of the transgene is lost. In addition, it shows the selection and accumulation of virus mutants that have lost the transgene or its expression.
Shape and size of virions
The shape and size of negatively stained purified virions were determined in order to ascertain whether there are differences in the virion 2D architecture of the virus strains under study. The results are shown in Figure 5 and Table 2. The virions of CPXV-NOHI were brick shaped measuring 293 ± 27 nm × 229 ± 23 nm in size (Figure 5A, Table 2). Virions of CPXV-NOH1 were slightly smaller than what has been reported for strains of vaccinia virus [26–28]. Conversely, half of the virions of MVA-HANP were brick shaped (314 ± 23 nm × 256 ± 18 nm) while the other half were round shaped with dimensions measuring 255 ± 28 nm × 243 ± 29 nm (Figure 5B, Table 2). Virions obtained from Rec 1, Rec 3, Rec 3a and Rec 3b resemble that of CPXV-NOH1 in being mostly brick shaped. Unlike CPXV-NOH1, a small percentage of virions obtained from the aforementioned progeny viruses have round shape (Figure 5, Table 2). Apparently the virions of Rec 2 appear to be a mixture of what was obtained from the parental strains. Two thirds of Rec 2 virions were brick shaped and the remaining one third were round in shape (Figure 5D, Table 2). The results indicated that the brick shape is the major virion shape in all virus strains except MVA-HANP.
We carried out detailed analysis of the morphogenesis of the virus strains under study by electron microscopy. Relative and absolute numbers of various mature and immature viral forms were determined at different times post infection. The kinetics of mature virus production in Vero cells is depicted in Figure 6. MVA-HANP results were not included because a very low level of mature virus forms were produced in Vero cells . Assembly of CPXV-NOHI and hybrid progenies was similar to what have been reported for strains of vaccinia virus [7, 29, 30]. Differences existed in the abundance of mature virus forms produced by CPXV-NOHI and progeny viruses. The intracellular mature virus (IMV) is the major mature virus type produced in CPXV-NOH1 infected cells accounting for 87% of virion forms (IMV, IEV, CEV) at 24 hpi (Figure 6A). Intracellular enveloped virus (IEV) and cell associated enveloped virus (CEV) represented 4% and 9% respectively of virion forms produced in CPXV-NOH1 infected cells (Figure 6A). Similarly, 95% of virions produced by Rec 1 at 24 hpi were IMVs (Figure 6B). However in Rec 2, a higher proportion of IMVs were converted to enveloped forms such that at 24 hpi, CEV is the predominant form representing 55% of virion forms produced (Figure 6C). Rec 3 appeared defective in the production of enveloped virions. At 18 and 24 hpi, less than 1% of Rec 3 virions were IEV or CEV (Figure 6D). Transgene negative derivatives of Rec 3 (Rec 3a and Rec 3b) were efficient in the production of enveloped virions. The enveloped forms (IEV and CEV) accounted for approximately 50% of virion types produced by Rec 3a and Rec 3b respectively at 24 hpi (Figures 6E, F).
Localization of the transgenic protein
We used immunogold cryo electron microscopy to track the localization of influenza virus HA protein produced by transgenic poxviruses in infected cells. The cellular and viral location of the transgenic protein was the same for all transgenic viruses (MVA-HANP, Rec 1, Rec 2, Rec 3), and was also independent of cell line used for virus cultivation. The transgenic protein was absent in IMVs and immature viruses (Figures 7A, C). The influenza virus HA protein was concentrated on the plasma membrane (Figures 7A–F), Golgi apparatus (Figure 7D), trans-Golgi membrane (Figure 7C), CEVs (Figures 7B, E), and EEVs (Figures 7F). Gold particles were also present in cell-associated vesicles (Figure 7D), vacuoles, cytoplasmic vesicles and exocytic vesicles (data not shown). Overall, the influenza virus HA protein was targeted to enveloped virions and cellular compartments associated with the down stream exocytic pathway. Also the transgenic HA protein targets are independent of virus backbone expressing the transgene as well as the cell line used for virus multiplication.
In this work we have investigated biological properties of progeny hybrid viruses obtained from recombination in vitro with a transgenic MVA candidate vaccine and a naturally circulating cowpox virus. The hypothesis of this work is that the extensive use of poxvirus-vectored vaccines in future might result in natural in vivo co-infection and recombination between poxvirus-vectored vaccines and naturally circulating orthopoxviruses resulting in hybrid viruses with non-parental characteristics. MVA and a naturally circulating cowpox virus were used as parental strains to test this hypothesis in vitro. MVA is arguably the vector of choice for antigen delivery , and the wide spread use of MVA vectored vaccines (especially in wild life and domestic animals) in the future is highly likely. Cowpox virus is the ancestor of other OPVs, has broad host range, and contains the most complete repertoire of immunomodulators [32–34]. Unlike vaccinia virus where DNAemia or viremia seems to be an extremely rare event in vaccinees , DNAemia in patients with localized symptoms of cowpox virus infection seem not to be a rare event . Indeed cowpox virus DNA was detected in whole blood of two independent patients at 4 weeks post infection . Persistence of cowpox virus DNA in infected individuals increases the likelihood of recombination during co-infection with a poxvirus-vectored vaccine. Thus homologous recombination between MVA vectored vaccine and a naturally circulating cowpox virus (or other orthopoxviruses) can occur and such a recombination has the potential of generating novel hybrid viruses that will elucidate our understanding of the biology of recombinant poxviruses, as well as the putative scenarios that might arise following the release of genetically modified poxviruses in the wild.
CPXV-NOH1 underwent productive infection in all the thirteen mammalian cell lines used in this study. This is consistent with the broad host range of other cowpox virus strains [37, 38]. The progeny viruses have cell line tropism similar to CPXV-NOHI, but not to MVA-HANP. Although few host range genes have been identified in cowpox virus , sequence analysis of OPV genomes indicated that host range genes cluster at the genome termini [32, 40]. Our previous work suggested that all the progeny viruses derived their genome termini from CPXV-NOH1 . Thus the hybrid viruses might have derived their host range genes from CPXV-NOH1. With the exception of Rec 3, progeny viruses have higher levels of CPE in most mammalian cell lines than the parental strains. A possible explanation is that progeny viruses have a more effective mechanism for the shutdown of host protein synthesis.
Progeny viruses displayed plaque phenotypes different from parental strains. The plaque phenotypes of the progenies were reproducible in all the cell lines (data not shown). Large lytic plaques are often associated with efficient cell to cell spread in cell cultures while small plaques may indicate inefficient cell to cell spread [41, 42]. The genetic basis of the plaque phenotypes in the parental and progeny viruses is unknown. However, in vaccinia virus Western Reserve (VACV-WR), it has been demonstrated that five EEV proteins (gene products of A33R, A34R, A56R, B5R, F13L) and two IEV proteins (A36R, F12L) may be involved in determining plaque phenotypes [43–49]. Although functionally intact EEV and IEV membrane proteins are associated with large plaque phenotype, they are insufficient in determining plaque size per se . It has also been reported that the production of actin tails is the major factor correlating with plaque size . Rec 2 plaques were characterized by the formation of comets. Comet formation was present, albeit to a lower degree in the parental MVA-HANP. Thus it is plausible that the genes for comet formation in Rec 2 were derived from MVA-HANP. In vaccinia virus IHD, comets are due to point mutation in the A34R open reading frame (ORF) or a second site mutation in the A33R and B5R ORFs [52, 53]. Rec 3b plaques displayed high degree of syncytium formation, a trait not observed in the parental strains and other progeny viruses. Mutation in the A56R is known to cause syncytia in vaccinia virus .
Three experimental observations made in this study have potential relevance for the release of genetically modified poxviruses into the ecosystem as well as recombination between transgenic poxviruses and naturally occurring relatives. Firstly, the transgene is deleted at high frequency in Rec 3 and MVA-HANP probably as a result of adaptation to the cell lines. Secondly, the viruses that have lost the transgene have higher virus multiplication compared to the transgene positive progenitor strain. Thirdly, there is variation in the stability of the transgene or its phenotype in different cell lines. The HA phenotype of Rec 2 was very stable in African Green Monkey derived Vero cells but became unstable in rat derived intestinal IEC-6 cells. The loss of the transgene/transgene phenotype as part of adaptation to new cells or hosts, the subsequent positive selection and accumulation of none transgene expressing virus mutants might compromise the efficacy of poxvirus vectored vaccines. The loss of the transgene will likely result in less effective vaccine since there will be less antigen to elicit robust immune responses. However since MVA undergoes abortive infection in most mammalian cell types, the accumulation of none transgene expressing viruses in the vaccinated hosts seem unlikely. The loss of the transgene or its phenotype and subsequent accumulation of none transgene expressing vector will be a likely problem for poxvirus vaccines based on replication competent vaccinia virus. The apparent variation in the stability of the HA transgene or the HA phenotype across different cell lines raises the possibility that the transgene inserted into poxviruses may have varying stability in different hosts. Although, spontaneous deletion  and truncation  of transgenes have been observed in some candidate MVA vectored vaccines, this is the first report showing that the same MVA or CPXV/MVA vectored vaccines was stable in one cell line and unstable in the other. Thus, our findings suggest that there is a host cell selection against the transgene. We have no explanation for the differential loss of the HA expression in different cell lines and among different viruses following serial passage. However, we speculate that the structure of the inserted HA transgene, the promoters driving the HA expression, the direction of the inserted HA transgene relative to the surrounding genes, the inherent stability/instability of the genetic locus at which the HA was inserted and the host cell responses to the HA protein are some of the factors that might affect the stability of the HA transgene or the loss of the HA expression following serial passage of the transgenic viruses. Genome wide mapping of these recombinant viruses will shed light on the genetic basis for the biological observations made in this study.
The purified virions of CPXV-NOH1 are brick shaped with highly corrugated surface similar to the structure of VACV-WR . The virions of MVA-HANP are pleomorphic with half of the virions being brick shaped and the other half round. The observation is in concert with a previous report . A 3D reconstruction of VACV-WR virions claimed that all IMVs are brick shaped and the observation of varied shapes in earlier studies is due to the limitation of 2D imaging . The round form observed in this study for MVA-HANP and the hybrid viruses (Figures 5B, D, E) is very close to a circle such that the difference between the length and width is 15 nm or less (Table 2). However, 2D measurements as done in this study can be affected by the angle of tilt as well as the plane at which the virions lie on the grids. Thus, our finding of spherical or round forms of virions especially in MVA need to be confirmed by 3D reconstruction of MVA and other OPV strains.
IMV is the major viral form produced in Vero cells infected with CPXV-NOH1. The dominance of IMVs over the enveloped forms may not be unconnected with the fact that CPXV-NOH1 produces V+ A-type inclusion (ATI) in infected cells (data not shown). It has been suggested that IMVs marked for sequestration into ATI may not differentiate into IEVs, CEVs or EEVs . Like CPXV-NOH1, IMVs constitute over 90% of virions produced in Vero cells infected with Rec 1 at various times post infection. However in Rec 2, the percentage of enveloped forms (IEV and CEV) is higher than that of IMV. Probably, the trans-Golgi network (TGN) wrapping and transport of IEV on microtubules is very efficient in Rec 2. Rec 3 on the other hand produces very low number of IEV or CEV and may be defective in the wrapping of IMV by the TGN. In Rec 3a and Rec 3b, the proportions of IMV and enveloped virions at 24 hpi were almost equal. Kinetics of virion formation in Rec 3a indicated high percentage of CEVs even though that of IEVs is low. It seems that some of the CEVs observed in Rec 3a infected cells were produced by plasma membrane budding of IMV rather than fusion of IEV outer envelope with the plasma membrane. Budding of IMVs through the plasma membrane has been shown to be an alternative mechanism for the production of CEVs .
The incorporation of influenza virus HA protein into the CEV and EEV of transgenic viruses has potential biosafety and immunological implications. Although foreign protein on the surface of CEVs and EEVs may enhance the humoral immune response of the host , they may also alter the host range or cell tropism of the transgenic MVA. Although MVA is host restricted and may not form sufficient CEVs/EEVs in human cells, the transgene on the MVA vector can be inserted by homologous recombination into another OPV with broad host range during mixed infection. Indeed we have shown in this work that the CEV and EEV of hybrid viruses incorporated the transgenic protein on their surface. We assume that the localization of the transgenic protein on CEV/EEV but not IMV or immature viruses is because the former derived its envelope from TGN or the plasma membrane [57, 59]. Both the TGN and plasma membrane were heavily labeled with gold particles. The cellular localization of the influenza virus transgenic protein is in agreement with other reports [60, 61]. The lack of gold particles on IMVs and immature viruses suggests that the IMV membrane is not derived from cellular membranes associated with the exocytic pathway.
We have shown that recombinant viruses obtained from co-infection of cells with MVA vectored influenza vaccine and a naturally circulating cowpox virus displayed parental, but also potentially important non-parental characteristics, which were not predictable from the outset. A major observation is that the transgene negative viruses have enhanced multiplication compared to the transgene positive progenitor virus strain, and that the host cell type may affect the stability of the transgene or its phenotype
Cells, viruses, and antibodies
All cell lines were purchased from the American Type Culture Collection (ATCC). Cells (Table 1) except A549 were cultured under conditions suggested by ATCC. A549 cells were propagated in Hams F12 medium supplemented with 20% foetal bovine serum (FBS) (Invitrogen AS, Karlruhe, Germany). The CPXV-NOH1 was originally isolated from a woman with necrotic ulcer . MVA-HANP was provided by Dr. Bernard Moss, National Institute of Health, USA. The genome of MVA-HANP contains influenza virus (A/PR/8/34) HA and NP inserts . CPXV-NOHI and MVA-HANP were parental viruses used for co-infection of BHK-21 cells. The isolation and restriction enzyme mapping of parental and progeny hybrid viruses was reported elsewhere . The progeny hybrid viruses are CPXV/MVA-Rec1 (Rec 1), CPXV/MVA-Rec2 (Rec 2), CPXV/MVA-Rec3 (Rec 3), CPXV/MVA-Rec3a (Rec 3a) and CPXV/MVA-Rec3b (Rec 3b). Rec 3a and Rec 3b are transgene negative derivatives of Rec 3 . The stock of parental and progeny viruses except MVA-HANP were prepared from infected Vero cells. MVA-HANP stock was prepared from infected BHK-21 cells. Anti influenza virus HA monoclonal antibody, H28E23 was a gift from Dr. Bernard Moss.
Plaques of viruses carrying the influenza virus HANP transgenes were visualized by immunostaining as described previously . Briefly, virus infected cells were fixed in 1:1 solution of methanol: acetone for 2 minutes. Anti influenza virus monoclonal antibody H28E23 was used as primary antibody in 1: 500 dilution. The secondary antibody, rabbit anti mouse IgG conjugated with peroxidase (Dako, Glostrop, Denmark) was used in 1:200 dilution. Both antibodies were diluted in phosphate buffered saline (PBS) supplemented with 3% FBS. DAB Peroxidase (Sigma Fast™ 3, 31diaminobenzidine tablet sets) was used as substrate (Sigma Aldrich Chemie Gmbh, Steinhein Germany). This staining method was used to determine the titre of the transgene positive virus strains under low and high m.o.i.
The titres of transgene negative viruses under low and high m.o.i were determined by plaque assay as described previously . Virus was adsorbed to cell monolayer for one hour at 37°C. The inoculum was removed and infected cells were incubated in fresh medium supplemented with 2.5% FBS at 37°C in a 5% CO2 atmosphere. After 36 hours, the medium was removed, and the infected cells were stained with crystal violet (0.1% in 20% ethanol) for 30 minutes. The cells were washed and air-dried.
Cell Line Permissivity Assay
Thirteen mammalian cell lines (Table 1) in 25 cm2 tissue culture flasks were infected with parental and progeny viruses at a m.o.i of 0.05 pfu or IU per cell. Following adsorption for one hour, the inocula were removed and cells were washed twice in PBS. Fresh medium supplemented with 2.5% FBS were added and incubation was carried out for 72 hpi. Cells and medium (supernatant) were harvested. Viruses in the cells were released by three cycles of freeze-thawing and brief sonication. Virus multiplication and CPE were quantified as reported previously .
Kinetics of virus multiplication
Vero and IEC-cell monolayers in 25 cm2 TC flasks were infected with respective virus strains at low (0.01 pfu/cell) and high (5.0 pfu/cell) m.o.i respectively. After adsorption for one hour at 37°C, the inocula were removed. Infected cells were washed twice in PBS and incubated in appropriate medium supplemented with 2.5% FBS at 37°C in a 5% CO2 atmosphere. At multiple times post infection, cells and supernatant were harvested. Virus titre in the cell lysate and supernatant were determined by plaque assay and immunostaining.
Transgene Stability Assay
The stability of the influenza virus HA insert present in the genome of the transgene positive viruses was monitored indirectly by immunostaining. Plaque purified transgene positive virus strains were passaged many times in Vero and IEC-6 cells at a m.o.i of 0.01 pfu per cell. After each passage, the infectious titre and the number of HA positive and HA negative plaques were quantified by immunostaining. Back titration of MVA-HANP was done in IEC-6 monolayers while that of other transgene positive virus strains were carried out in Vero cells.
Transmission Electron Microscopy
Cell monolayers in six well tissue culture plates (NUNC Sweden) were infected with parental and progeny viruses at a m.o.i of 5 pfu per cell. Adsorption was for one hour at 4°C. The cells were washed thrice in PBS and incubated in fresh medium containing 2.5% FBS at 37°C in 5% CO2 atmosphere. At 6, 12, 18, and 24 hpi, the medium was removed. Infected cells were rinsed with fresh medium, and fixed in MacDowells solution, pH 7.4 containing 1% glutaraldehyde and 4% formaldehyde in PBS. Fixed cells were processed for electron microscopy as reported elsewhere . Mature and immature forms of parental and progeny viruses were counted in 50 cell sections that were infected. Absolute and relative amount of viral forms were calculated. Collection of images from thin sections was done using JEOL 1010 electron microscope operating at an accelerating voltage of 100 KV.
Parental and progeny virions were semi-purified from infected cells by pelleting through a sucrose cushion . Purified virions were negatively stained with 1% phosphotungstic acid, pH 6.2. Stained virions were adsorbed to formvar coated grids. Virions were visualized in a JEOL JEM – 1010 electron microscope. The shape and dimensions of 50 virions were determined for each of the virus strains under study.
Cryo-immunogold Electron Microscopy
Monolayers of Vero, IEC-6, and A549 cells were infected with parental and progeny virus strains at a m.o.i of 5 pfu or IU per cell. Virus adsorption was for one hour at 4°C. Cells were washed in PBS and incubated in a fresh medium supplemented with 2.5% FBS under standard conditions. At 12 and 24 hpi, the culture medium was removed and infected cells were rinsed with PBS, fixed overnight in 4% formaldehyde – 0.1% glutaraldehyde in Hepes buffer, pH 7.4. Fixed cells were pelleted, resuspended in 10% gelatin and infiltrated in 2.3 M sucrose. Infiltrated cells were processed for pre-embedding immunogold labeling . Anti-influenza virus HA monoclonal antibody H28E23 diluted 1: 400 in 1% cold water fish gelatin, CWFSG (Sigma G-7765) was used as the primary antibody. The influenza virus HA monoclonal antibody was detected with rabbit anti mouse IgG (diluted 1: 400 in CWFSG) conjugated to 10 nm gold particles. The localization of the transgenic protein in the cellular and viral structures was documented with JEOL 1010 electron microscope.
Pastoret PP, Vanderplasschen A: Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003, 26: 343-355. 10.1016/S0147-9571(03)00019-5
Brochier B, Aubert MF, Pastoret PP, Masson E, Schon J, Lombard M, Chappuis G, Languet B, Desmettre P: Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev Sci Tech 1996, 15: 947-970.
Nemeckova S, Hainz P, Otahal P, Gabriel P, Sroller V, Kutinova L: Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. Acta Virol 2001, 45: 243-247.
Vanderplasschen A, Pastoret PP: The uses of poxviruses as vectors. Curr Gene Ther 2003, 3: 583-595. 10.2174/1566523034578168
Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA: Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001, 75: 1205-1210. 10.1128/JVI.75.3.1205-1210.2001
Hansen H, Okeke MI, Nilssen O, Traavik T: Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene. Vaccine 2004, 23: 499-506. 10.1016/j.vaccine.2004.06.032
Okeke MI, Nilssen O, Traavik T: Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. J Gen Virol 2006, 87: 21-27. 10.1099/vir.0.81479-0
Drexler I, Heller K, Wahren B, Erfle V, Sutter G: Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998,79(Pt 2):347-352.
Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, Kwast T, Wyatt LS, Moss B, Osterhaus AD: Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19: 3700-3709. 10.1016/S0264-410X(01)00075-5
Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H: Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch Virol 2003, 148: 827-839. 10.1007/s00705-003-0006-z
Hanke T, McMichael AJ, Dennis MJ, Sharpe SA, Powell LA, McLoughlin L, Crome SJ: Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005, 23: 1507-1514. 10.1016/j.vaccine.2004.08.050
Corona Gutierrez CM, Tinoco A, Lopez Contreras M, Navarro T, Calzado P, Vargas L, Reyes L, Posternak R, Rosales R: Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 2002, 13: 1127-1140. 10.1089/104303402753812520
Drexler I, Staib C, Sutter G: Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004, 15: 506-512. 10.1016/j.copbio.2004.09.001
Wyatt LS, Earl PL, Eller LA, Moss B: Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004, 101: 4590-4595. 10.1073/pnas.0401165101
Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, et al.: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005, 113: 259-266. 10.1002/ijc.20569
Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J, Lang T, Hill AV, Marsh K: Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006, 42: 1102-1110. 10.1086/501459
Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H: Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest 2008, 118: 1776-1784. 10.1172/JCI33940
Chernos VI, Antonova TP, Senkevich TG: Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents. J Gen Virol 1985,66(Pt 3):621-626. 10.1099/0022-1317-66-3-621
Ball LA: High-frequency homologous recombination in vaccinia virus DNA. J Virol 1987, 61: 1788-1795.
Fathi Z, Dyster LM, Seto J, Condit RC, Niles EG: Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus. J Gen Virol 1991,72(Pt 11):2733-2737. 10.1099/0022-1317-72-11-2733
Block W, Upton C, McFadden G: Tumorigenic poxviruses: genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus. Virology 1985, 140: 113-124. 10.1016/0042-6822(85)90450-7
Gershon PD, Kitching RP, Hammond JM, Black DN: Poxvirus genetic recombination during natural virus transmission. J Gen Virol 1989,70(Pt 2):485-489. 10.1099/0022-1317-70-2-485
Willer DO, Mann MJ, Zhang W, Evans DH: Vaccinia virus DNA polymerase promotes DNA pairing and strand-transfer reactions. Virology 1999, 257: 511-523. 10.1006/viro.1999.9705
Yao XD, Evans DH: Effects of DNA structure and homology length on vaccinia virus recombination. J Virol 2001, 75: 6923-6932. 10.1128/JVI.75.15.6923-6932.2001
Carroll MW, Moss B: Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238: 198-211. 10.1006/viro.1997.8845
Cyrklaff M, Risco C, Fernandez JJ, Jimenez MV, Esteban M, Baumeister W, Carrascosa JL: Cryo-electron tomography of vaccinia virus. Proc Natl Acad Sci USA 2005, 102: 2772-2777. 10.1073/pnas.0409825102
Gallego-Gomez JC, Risco C, Rodriguez D, Cabezas P, Guerra S, Carrascosa JL, Esteban M: Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol 2003, 77: 10606-10622. 10.1128/JVI.77.19.10606-10622.2003
Dubochet J, Adrian M, Richter K, Garces J, Wittek R: Structure of intracellular mature vaccinia virus observed by cryoelectron microscopy. J Virol 1994, 68: 1935-1941.
Hollinshead M, Rodger G, Van Eijl H, Law M, Hollinshead R, Vaux DJ, Smith GL: Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol 2001, 154: 389-402. 10.1083/jcb.200104124
Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu W, Xiao G, Tien P, Zhang L, Chen Z: Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005, 335: 242-251. 10.1016/j.virol.2005.02.014
Staib C, Drexler I, Sutter G: Construction and isolation of recombinant MVA. Methods Mol Biol 2004, 269: 77-100.
Gubser C, Hue S, Kellam P, Smith GL: Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004, 85: 105-117. 10.1099/vir.0.19565-0
Shchelkunov SN, Safronov PF, Totmenin AV, Petrov NA, Ryazankina OI, Gutorov VV, Kotwal GJ: The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 1998, 243: 432-460. 10.1006/viro.1998.9039
Lefkowitz EJ, Wang C, Upton C: Poxviruses: past, present and future. Virus Res 2006, 117: 105-118. 10.1016/j.virusres.2006.01.016
Cummings JF, Polhemus ME, Hawkes C, Klote M, Ludwig GV, Wortmann G: Lack of vaccinia viremia after smallpox vaccination. Clin Infect Dis 2004, 38: 456-458. 10.1086/381101
Nitsche A, Kurth A, Pauli G: Viremia in human Cowpox virus infection. J Clin Virol 2007, 40: 160-162. 10.1016/j.jcv.2007.07.014
Baxby D, Bennett M, Getty B: Human cowpox 1969–93: a review based on 54 cases. Br J Dermatol 1994, 131: 598-607. 10.1111/j.1365-2133.1994.tb04969.x
Baxby D, Bennett M: Cowpox: a re-evaluation of the risks of human cowpox based on new epidemiological information. Arch Virol Suppl 1997, 13: 1-12.
Ramsey-Ewing A, Moss B: Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. Virology 1995, 206: 984-993. 10.1006/viro.1995.1021
Upton C, Slack S, Hunter AL, Ehlers A, Roper RL: Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J Virol 2003, 77: 7590-7600. 10.1128/JVI.77.13.7590-7600.2003
Roper RL, Wolffe EJ, Weisberg A, Moss B: The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J Virol 1998, 72: 4192-4204.
Wolffe EJ, Katz E, Weisberg A, Moss B: The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J Virol 1997, 71: 3904-3915.
Roper RL, Payne LG, Moss B: Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol 1996, 70: 3753-3762.
McIntosh AA, Smith GL: Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol 1996, 70: 272-281.
Shida H: Nucleotide sequence of the vaccinia virus hemagglutinin gene. Virology 1986, 150: 451-462. 10.1016/0042-6822(86)90309-0
Engelstad M, Howard ST, Smith GL: A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 1992, 188: 801-810. 10.1016/0042-6822(92)90535-W
Hirt P, Hiller G, Wittek R: Localization and fine structure of a vaccinia virus gene encoding an envelope antigen. J Virol 1986, 58: 757-764.
van Eijl H, Hollinshead M, Smith GL: The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. Virology 2000, 271: 26-36. 10.1006/viro.2000.0260
van Eijl H, Hollinshead M, Rodger G, Zhang WH, Smith GL: The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. J Gen Virol 2002, 83: 195-207.
Smith GL, Law M: The exit of vaccinia virus from infected cells. Virus Res 2004, 106: 189-197. 10.1016/j.virusres.2004.08.015
Smith GL, Vanderplasschen A, Law M: The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002, 83: 2915-2931.
Blasco R, Sisler JR, Moss B: Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 1993, 67: 3319-3325.
Katz E, Wolffe E, Moss B: Identification of second-site mutations that enhance release and spread of vaccinia virus. J Virol 2002, 76: 11637-11644. 10.1128/JVI.76.22.11637-11644.2002
Seki M, Oie M, Ichihashi Y, Shida H: Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. Virology 1990, 175: 372-384. 10.1016/0042-6822(90)90422-N
Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B: Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008, 372: 260-272. 10.1016/j.virol.2007.10.033
Ulaeto D, Grosenbach D, Hruby DE: The vaccinia virus 4c and A-type inclusion proteins are specific markers for the intracellular mature virus particle. J Virol 1996, 70: 3372-3377.
Meiser A, Sancho C, Krijnse Locker J: Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. J Virol 2003, 77: 9931-9942. 10.1128/JVI.77.18.9931-9942.2003
Katz E, Moss B: Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. AIDS Res Hum Retroviruses 1997, 13: 1497-1500. 10.1089/aid.1997.13.1497
Schmelz M, Sodeik B, Ericsson M, Wolffe EJ, Shida H, Hiller G, Griffiths G: Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 1994, 68: 130-147.
Keller P, Simons K: Cholesterol is required for surface transport of influenza virus hemagglutinin. J Cell Biol 1998, 140: 1357-1367. 10.1083/jcb.140.6.1357
Krauss O, Hollinshead R, Hollinshead M, Smith GL: An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol 2002, 83: 2347-2359.
Tryland M, Sandvik T, Hansen H, Haukenes G, Holtet L, Bennett M, Mehl R, Moens U, Olsvik O, Traavik T: Characteristics of four cowpox virus isolates from Norway and Sweden. Apmis 1998, 106: 623-635.
Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B: A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12: 1032-1040. 10.1016/0264-410X(94)90341-7
McKelvey TA, Andrews SC, Miller SE, Ray CA, Pickup DJ: Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions. J Virol 2002, 76: 11216-11225. 10.1128/JVI.76.22.11216-11225.2002
Pedersen K, Snijder EJ, Schleich S, Roos N, Griffiths G, Locker JK: Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure. J Virol 2000, 74: 3525-3536. 10.1128/JVI.74.8.3525-3536.2000
Carter GC, Law M, Hollinshead M, Smith GL: Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol 2005, 86: 1279-1290. 10.1099/vir.0.80831-0
This work was supported by the Norwegian Research Council (project no. 148535/v110), the University of Tromsø, Norway, and GenØk-Center for Biosafety Tromsø, Norway. We thank Randi Olsen and Helga-Marie Bye of the Department of Electron Microscopy, University of Tromsø, Norway for their technical assistance.
The authors declare that they have no competing interests.
MIO designed the study, carried out all experiments, and wrote the draft of the manuscript. ØN contributed to the design of the study, interpreted data and revised the manuscript. UM interpreted the data and revised the manuscript. MT interpreted data and revised the manuscript. TT conceived the study, contributed to its design, interpreted data and revised the manuscript. All authors' have read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Okeke, M.I., Nilssen, Ø., Moens, U. et al. In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate. Virol J 6, 55 (2009). https://doi.org/10.1186/1743-422X-6-55
- Influenza Virus
- Vero Cell
- Progeny Virus
- Transgenic Protein
- Modify Vaccinia Virus Ankara